beta-amyloid 42 (Aβ42) antibody and antigen (Recombinant protein)

Diagnostic beta-amyloid 42 (Aβ42) antibodies (anti-beta-amyloid 42, anti-Aβ42) and antigens (recombinant beta-amyloid 42 (Aβ42) protein) for Neurodegenerative diseases Aβ42 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.

Target products collectionGo to Neurodegenerative diseases diagnostics products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-h-Aβ42-Ag01 Recombinant human APP/Aβ42/A4/AD1 Protein 3090
GMP-h-Aβ42-Ab01 Anti-human APP/Aβ42/A4/AD1 mouse monoclonal antibody (mAb) 1953
GMP-h-Aβ42-Ab02 Anti-human APP/Aβ42/A4/AD1 mouse monoclonal antibody (mAb) 1953
GMP-h-Aβ42-Ab03 Anti-human APP/Aβ42/A4/AD1 human monoclonal antibody (mAb) 1953
GMP-h-Aβ42-Ab04 Anti-human APP/Aβ42/A4/AD1 human monoclonal antibody (mAb) 1953

Size： 1mg | 10mg | 100mg



Product Description

Cat No. of Products GMP-h-Aβ42-Ag01
Product Name Recombinant human APP/Aβ42/A4/AD1 Protein
Target/Biomarker beta-amyloid 42 (Aβ42)
Alias of Target/Biomarker AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4
Expression platform mammalian
Isotypes Recombinant Antigen
Bioactivity validation beta-amyloid 42 (Aβ42) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease (AD)) and related syndrome evaluation.
Tag His
Products description Recombinant human APP/Aβ42/A4/AD1 Protein was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products GMP-h-Aβ42-Ab01, GMP-h-Aβ42-Ab02
Product Name Anti-human APP/Aβ42/A4/AD1 mouse monoclonal antibody (mAb)
Target/Biomarker beta-amyloid 42 (Aβ42)
Alias of Target/Biomarker AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation beta-amyloid 42 (Aβ42) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease (AD)) and related syndrome evaluation.
Tag mFc
Products description Anti-human APP/Aβ42/A4/AD1 mouse monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products GMP-h-Aβ42-Ab03, GMP-h-Aβ42-Ab04
Product Name Anti-human APP/Aβ42/A4/AD1 human monoclonal antibody (mAb)
Target/Biomarker beta-amyloid 42 (Aβ42)
Alias of Target/Biomarker AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4
Expression platform CHO
Isotypes Human lgG1
Bioactivity validation beta-amyloid 42 (Aβ42) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease (AD)) and related syndrome evaluation.
Tag hFc
Products description Anti-human APP/Aβ42/A4/AD1 human monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Validation Data


    Good performance of GeneMedi's Aβ40/Aβ42 antibodies in ELISA and CLIA Validation

    The high-performance Aβ40 and Aβ42 antibody raw materials developed by GeneMedi have the advantages of good specificity and high sensitivity, and are the preferred raw materials for the development of in vitro diagnostics reagents for Alzheimer's disease.
    In direct ELISA analysis, GMP-h-Aβ40-Ab01 and GMP-h-Aβ42-Ab01 can Recognizes Aβ40 or Aβ42 with high specificity. GMP-h-Aβ42-Ab02 has cross-reactivity with both Aβ40 and Aβ42.
    In CLIA verification, the antibody pair (Capture: GMP-h-Aβ40-Ab01 , Detect: GMP-h-Aβ42-Ab02 ) can detect the GMP-h-Aβ40-Ag01, and the antibody pair (Capture: GMP-h-Aβ42-Ab02 , Detect: GMP-h-Aβ42-Ab01 ) can detect the GMP-h-Aβ42-Ag01. Beta-amyloid(1-42) antibodies (GMP-h-Aβ42-Ab02 and GMP-h-Aβ42-Ab01) established a standard curve, and the detection range of Aβ42 was 100-1700 pg/mL.

    Figure 1: Good performance of GeneMedi's Aβ40/Aβ42 antibodies in ELISA and CLIA Validation

    A. GMP-h-Aβ40-Ab01 and GMP-h-Aβ42-Ab02 can bind GMP-h-Aβ40-Ag01, while GMP-h-Aβ42-Ab01 can not bind the Aβ40 antigen in direct ELISA.
    B. GMP-h-Aβ42-Ab01 and GMP-h-Aβ42-Ab02 can bind GMP-h-Aβ42-Ag01, while GMP-h-Aβ40-Ab01 can not bind the Aβ42 antigen in direct ELISA.
    C. CLIA verification data of the antibody pair (Capture: GMP-h-Aβ40-Ab01 , Detect: GMP-h-Aβ42-Ab02 ) to detect the GMP-h-Aβ40-Ag01.
    D. CLIA verification data of the antibody pair (Capture: GMP-h-Aβ42-Ab02 , Detect: GMP-h-Aβ42-Ab01 ) to detect the GMP-h-Aβ42-Ag01.

    Aβ42 validation

    Click to Zoom

    Click to get more Data / Case study about the product.



    Target/Biomarker information

    Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies. Low plasma Aβ42/40 was associated with more pronounced decline in cognitive function (measured by multiple outcomes) over time. Findings suggest that plasma Aβ42/40 may be used to identify people at risk of cognitive decline, being an alternative to more complex and expensive measures, such as positron emission tomography imaging or cerebrospinal fluid measurement.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.

    Comments


    No comments yet.

    Leave a comment